A. P. Kolpaksidi

A. P. Kolpaksidi

Auto-generated profile, based on publicly available information

A. P. Kolpaksidi

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
IKI. P. Kolpaksidi
I. P. Kolpaksidi
MDM. V. Dmitrieva
M. V. Dmitrieva
IYI. V. Yarosh
I. V. Yarosh
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
The aimof the work is to generalize the literature data on indolocarbazole derivatives with an antitumor activity.Materials and methods.The objects of the study were the preparations based on indolocarbazole derivatives with the antitumor activity. To search for materials on the problem under study, the following search and information as well as library databases were used: ebibrary, PubMed, CyberLeninka, ResearchGate, the State Register of Medicines, clinical trials registries clinline.ru and clinicaltrials.gov. The search for the following words / phrases was performed: indolocarbazoles, indolocarbazole derivatives, staurosporine, rebeccamycin, staurosporine derivatives. The search was conducted from January 11 until March 1, 2021. The compounds with a biological activity which were undergoing or had undergone preclinical and clinical trials, were taken into account. All the materials from 1977 to January 1, 2021, were taken into account.Results.The materials obtained indicate that indolocarbazole derivatives are promising compounds for the creation of anticancer medicinal preparations due to their properties and peculiarities of the action mechanism. These drugs have a selective action due to the targeted interaction with specific molecular targets: kinases (especially protein kinase C and its isozymes), DNA and DNA topoisomerase. To date, many compounds from the class of indolocarbazoles have been synthesized and investigated. They have shown a high antitumor activity in the treatment of systemic and solid tumors. However, despite this, only one MP based on a staurosporine derivative, registered by the TN of Rydapt® (in the USA and EU countries) and Miticaid® (in the Russian Federation), is approved for use in the clinical practice.Conclusion.Thus, the basic data from scientific publications on promising anticancer medicinal preparations based on compounds from the class of indolocarbazoles, have been summarized. The information is provided, in particular, on their molecular structure, the origin, classification, the main representatives of the class, which are at various stages of the research and are approved for use in the clinic.

31 October 2022 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
EIE. V. Ignatieva
E. V. Ignatieva
IYI. V. Yartseva
I. V. Yartseva
ZSZoya Shprakh
Zoya Shprakh
AKA. P. Kolpaksidi
A. P. Kolpaksidi
MDM. V. Dmitrieva
M. V. Dmitrieva
IPI. R. Prosalkova
I. R. Prosalkova
Background. A glycoside derivative of indolocarbazole LHS-1269, one of the new drugs selectively affecting tumors, which was first synthesized at the N.N. Blokhin National Medical-Research Center of Oncology of the Ministry of Health of Russia, is of particular scientific interest. Experimental studies demonstrated a multi-target mechanism of action of this compound. LHS-1269 interacts with several intracellular targets and induces various pathways of cell death. Several innovative models of the dosage forms were designed to achieve the highest antitumor activity of the compound and to perform further preclinical studies.Aim. To develop the methods for the quantitative determination of LHS-1269 in pharmaceutical compositions proposed as a result of the search for the optimal dosage form.Materials and methods. The study analyzed the spectrophotometric characteristics of LHS-1269 solutions in dimethylformamide, dimethylsulfoxide (DMSO) and in the mixture of solvents DMSO–ethyl alcohol, as well as electronic absorption spectra of the excipients in the mixture of solvents DMSO–ethyl alcohol. Spectrophotometric measurements were performed on a Cary 100 spectrophotometer (Varian, Inc., Australia) in the wavelength range from 200 to 500 nm. The standard sample is the substance LHS-1269 (N.N. Blokhin Oncology Research Center of the Ministry of Health of Russia).Results. The carried out studies showed that LHS-1269 solutions in dimethylformamide, DMSO and mixture of DMSO– ethyl alcohol are suitable for spectrophotometric measurements. Several variants of the methodology for the assay of LHS-1269 in various dosage form models that differ in the content of the active substance and the excipients composition have been developed: LHS-1269 concentrate for solution for injection and infusion; lyophilisate for solution for injection; liposomal lyophilisate for dispersion for injection.Conclusion. Techniques for the assay of LHS-1269 in dosage form models have been developed. It has been shown that the developed techniques are applicable for LHS-1269 quantitative determination in innovative dosage forms containing polymeric low molecular weightsolubilizers, lipids, cholesterol, mono- or oligosaccharides as excipients.

16 April 2025 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
GOG. A. Oborotov
G. A. Oborotov
MDM. V. Dmitrieva
M. V. Dmitrieva
AKA. P. Kolpaksidi
A. P. Kolpaksidi
SSS. D. Shceglov
S. D. Shceglov
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
Background. Chemotherapy remains the mainstay of drug treatment for malignant neoplasms, but its effectiveness is often limited by the development of drug resistance, low selectivity, and toxicity of the drugs used. Gemcitabine therapy, one of the most commonly used chemotherapeutic drugs, has many limitations, such as a short half-life and rapid degradation of the drug in the body. To improve the therapeutic efficacy of gemcitabine, two main strategies have been proposed – chemical modification of the compound and the creation of delivery systems based on various nanocarriers, in particular liposomes.Aim. To systematize and summarize the literature data on the prospects of developing a liposomal gemcitabine delivery system.Materials and methods. The search for materials on the topic under study was carried out using the search and information and library databases PubMed, CyberLeninka, e-Library, ResearchGate. The search for publications was carried out for the period from 1997 to 2025 using keywords / phrases: “liposomes”, “liposome encapsulation”, “liposomal gemcitabine”, “liposomal gemcitabine pharmacokinetics”, etc.Results. To date, numerous models of liposomal forms of gemcitabine have been developed and are at the preclinical development stage, and only one of them, FF-10832, has reached phase I of clinical trials. According to the results of a comparative study of the traditional and nanostructured forms of gemcitabine presented in the analyzed publications, liposomal gemcitabine demonstrates a higher therapeutic effect in in vivo experiments due to increased bioavailability and targeted delivery to tumor cells. However, the main problem in creating an optimal liposomal composition of gemcitabine remains the low level of drug encapsulation in vesicles, which can be overcome by selecting a lipid composition or developing a rational loading method.Conclusion. The literature data on the use of gemcitabine in the treatment of malignant neoplasms and the prospects for developing its liposomal delivery system have been systematized and summarized. It has been shown that the inclusion of gemcitabine in liposomes allows eliminating the problems associated with antitumor therapy with this drug.

24 November 2022 in Drug development & registration
Verified
Journal Article
Open access
PDF file
AKA. P. Kolpaksidi
A. P. Kolpaksidi
MDM. V. Dmitrieva
M. V. Dmitrieva
OOO. L. Orlova
O. L. Orlova
LEL. V. Ektova
L. V. Ektova
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
Introduction. N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia synthesized an original derivative of indolocarbazole with the carbohydrate residue xylose, which has a pronounced cytotoxic and anti-angiogenic activity. The substance LCS-1269 is an amorphous powder that is almost insoluble in water, which causes difficulties in the development of an injectable dosage form (IDP). To solve this problem, a technological approach to obtain a solid dispersion (SD) of LCS-1269 has been proposed.Aim. To develop a model of IDP of the indolocarbazole derivative LCS-1269 based on SD.Materials and methods. We used a substance LCS-1269 synthesized in the Chemical Synthesis Laboratory of the N. N. Blokhin National Medical Research Center of Oncology. Emuxol 268, Kolliphor® P 188, Soluplus®, Lutrol® F68, Kollidon® 12 and Kollidon® 17, soybean phosphatidylcholine unsaturated S PC and saturated S PC-3 were investigated as carriers of the active substance. SD LCS-1269 was obtained by solvent removal: the active substance was dissolved in acetone, the carrier − in chloroform, the obtained solutions were mixed, transferred into a bottle and evaporated under vacuum (50 ± 5 mbar) in the desiccator at water bath temperature 65 ± 2 °С. To obtain aqueous solution of LCS-1269 dry mass was dissolved using different auxiliary substances or their mixtures: water for injection, ethanol 95 %, benzyl alcohol, Kollisolv® PEG 400, MONTANOX™ 80. To increase stability, the aqueous solution of LCS-1269 was lyophilized in an Edwards Minifast DO.2 freeze dryer.Results and discussion. Kollidon® 17 was chosen as the carrier material for the SD active substance. It was found that a clear solution of LCS-1269 with the concentration of the active substance 0.5 % was formed by dissolving the SD in ethanol 95 % and then gradually diluting the alcohol mixture with water for injection. In this case, the mass ratio of the components of the developed model IDF LCS : Kollidon® 17 : ethanol : water is 1 : 40 : 32 : 127. As a result of freeze-drying of the water-ethanol solution of LCS-1269 the IDF in the form of lyophilizate easily soluble in a 10 % solution of ethanol was obtained.Conclusion. An IDF model of the hydrophobic derivative of indolocarbazole LCS-1269 based on SD was developed and submitted for biological studies to evaluate its effectiveness.

27 February 2023 in Drug development & registration
Verified
Journal Article
Open access
PDF file
AKA. P. Kolpaksidi
A. P. Kolpaksidi
MDM. V. Dmitrieva
M. V. Dmitrieva
LNLudmila Nikolaeva
Ludmila Nikolaeva
OOO. L. Orlova
O. L. Orlova
I(Ivan I. Krasnyuk (Jr.)
Ivan I. Krasnyuk (Jr.)
Introduction. LHS-1269 is an indolocarbazole derivative with high antitumor activity. Due to the hydrophobic properties of the active substance, the use of organic co-solvents – dimethyl sulfoxide (DMSO) and ethanol – is required to obtain an injectable dosage form (DP). However, the inclusion of organic solvents in the composition of the DF carries a potential risk of side effects as a result of the use of the drug.Aim. Selection of auxiliary substances for obtaining an aqueous solution of hydrophobic indolecarbazole derivative, which allows minimizing the concentration of organic solvents in the composition of DF.Materials and methods. The object of the study is the active substance LHS-1269 series 010320, produced in the Chemical Synthesis Laboratory of the N. N. Blokhin National Medical Research Center of Oncology. The following auxiliary substances were used to obtain model compositions: Kollidon® 17 PF, Kollisolv® PEG-400, Kolliphor® P 188, Montanox™ 20, DMSO (p.a.), ethanol 95 % (standardized according to pharmacopoeia quality standard ФС.2.2.0019.18 of The State Pharmacopoeia of the Russian Federation). Analytical scales OHAUS Analytical Plus AP 100S and laboratory scales AND DL-120 were used for weighing LHS-1269 and auxiliary substances. The dissolution and mixing of the components was carried out on an IKA® C-MAG HS 4 magnetic stirrer.Results and discussion. In the course of the study, 2 groups of model compositions were obtained and estimated, comprising a complex of two or more auxiliary substances as a solubilizer. The first group of formulations contained DMSO at a concentration of 5 % and ethanol at concentrations from 0 to 15 %. The compositions of the second group included DMSO from 0 to 4 %. As a result, it was found that the addition of 5 % Kolliphor® P 188 to the composition of the solution reduces the content of ethanol to 5 %. In this case, with further decrease in ethanol, turbidity of the solution and precipitation are observed. Reducing the concentration of DMSO in the DF to 2 % was achieved by using a combination of 20 % ethanol and solubilizer complex – Kollidon® 17 (20 %), Kollisolv® PEG-400 (20 %) and Kolliphor® P 188 (5 %). In this case, the total dissolution of the active substance without DMSO was observed when compensating for the organic solvent by introducing additional auxiliary substances – Montanox™ 20 (5 %) and benzene (2 %).Conclusion. As a result of the research, the compositions of the auxiliary substances of solubilizers are selected, allowing to obtain an aqueous solution of the hydrophobic compound LHS-1269 with a minimum concentration of organic solvents.

3 April 2026 in Drug development & registration
Verified
Journal Article
Open access
PDF file
ALAnna Lantsova
Anna Lantsova
ESEkaterina Sanarova
Ekaterina Sanarova
OOO. L. Orlova
O. L. Orlova
AKA. P. Kolpaksidi
A. P. Kolpaksidi
NON. A. Oborotova
N. A. Oborotova
ZSZoya Shprakh
Zoya Shprakh
Introduction. Maintaining the basic quality parameters of a drug is the key to its successful use in clinical practice. Productive use of the results of risk identification and assessment allows us to guarantee the effectiveness and safety of medicines through preventive measures to identify and eliminate potential threats to quality during their development and production. Aim. The aim of the study was to identify critical points in the technological process of obtaining a lyophilized dosage form of a compound from the class of indolocarbazoles LCS-1269 using a risk-based approach. Materials and methods. To analyze the risks in the technology for obtaining a lyophilisate based on LCS-1269, the risk management analysis tools and methods presented in the ICH Q8, Q9, Q10, State Pharmacopoeia of Russia XV ed. and ISO 31000-2019 guidelines were used. Results and discussion. When identifying risks of the production process, the main critical process parameters and critical control points were identified, among which the most important are compliance with the mode of dissolution of the pharmaceutical substance and excipients, filtration of the resulting solution and its lyophilization, as well as control over the main quality indicators characteristic of lyophilized dosage forms for parenteral use. Conclusion. The application of the selected approach made it possible to identify and assess possible risks to product quality at different stages of production of the drug "LCS-1269, lyophilisate for preparation of injection solution 25 mg" and to develop a strategy to eliminate or mitigate these risks and achieve the necessary goals, namely, obtaining high-quality, effective and safe drugs.